CN104173853A - Drug for treating ocular myasthenia gravis - Google Patents
Drug for treating ocular myasthenia gravis Download PDFInfo
- Publication number
- CN104173853A CN104173853A CN201410464437.0A CN201410464437A CN104173853A CN 104173853 A CN104173853 A CN 104173853A CN 201410464437 A CN201410464437 A CN 201410464437A CN 104173853 A CN104173853 A CN 104173853A
- Authority
- CN
- China
- Prior art keywords
- parts
- myasthenia gravis
- radix
- drug
- medicament
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention relates to a drug for treating ocular myasthenia gravis. The drug is prepared from the following substances in parts by weight: 20-60 parts of astragalus, 15-60 parts of radix codonopsis, 10-20 parts of white atractylodes rhizome, 10-30 parts of poria cocos, 10-20 parts of rhizoma cimicifugae, 10-20 parts of radix bupleuri, 10-15 parts of fruit of Chinese wolfberry, 10-30 parts of Chinese angelica, 10-15 parts of dried tangerine or orange peel, 10-25 parts of seed of Chinese dodder, 10-30 parts of semen coicis, 10-20 parts of malts, 10-15 parts of Chinese yam, 10-20 parts of pulp of dogwood fruit and 5-10 parts of prepared radix licorice. The drug for treating ocular myasthenia gravis is prepared from natural components, has good safety, is clear in curative effect, and is suitable for being clinically popularized on a large scale.
Description
Technical field
The present invention relates to field of medicaments, relate in particular to a kind of medicament for the treatment of ocular myasthenia gravis.
Background technology
Myasthenia gravis is a kind of acquired autoimmune disease of neuromuscular junction propagation function obstacle, impaired mainly due to acetylcholinergic receptor on nerve-muscle postsynaptic membrane due to.Often with blepharoptosis, primary symptom of diplopia, clinical ocular type, whole body type, acute severe type, tardy serious symptom type, amyotrophy type 5 types of being divided into of doctor trained in Western medicine, wherein ocular type is through treatment prognosis the best, the methods such as hormone, immunosuppressant, anticholinergic medicine, plasmapheresis, thymusectomy that adopt at present more, but these methods courses for the treatment of is long, expense is high, side effect is large, and easily recurrence, doctor trained in Western medicine does not have a kind of effective therapy up to now.Myasthenia gravis belongs to the traditional Chinese medical science " myopathy " category, because deficiency of spleen-QI and stomach-QI mostly is common pattern of syndrome, for myasthenia gravis (doctor trained in Western medicine typing: ocular type; Chinese medical discrimination: syndrome of deficiency of spleen qi and stomach qi), disease sees that order eyeball rotates ineffective with the ptosis or companion stravismus, diplopia, and companion sees extremity asthenia, and deficiency of QI with disinclination to talk, breathes hard uncomfortable in chest, indigestion and loss of appetite lack of appetite, pale tongue, white and thin fur, deep pulse person's curative effect is good.
Summary of the invention
The object of this invention is to provide a kind of medicament for the treatment of ocular myasthenia gravis.
In order to realize object of the present invention, the invention provides a kind of medicament for the treatment of ocular myasthenia gravis, it is to be made up of the material of following weight proportioning: 20～60 parts of the Radixs Astragali, 15～60 parts of Radix Codonopsis, 10～20 parts of the Rhizoma Atractylodis Macrocephalaes, 10～30 parts, Poria, 10～20 parts of Rhizoma Cimicifugaes, 10～20 parts of Radix Bupleuri, 10～15 parts of Fructus Lycii, 10～30 parts of Radix Angelicae Sinensis, 10～15 parts of Pericarpium Citri Reticulataes, 10～25 parts of Semen Cuscutae, 10～30 parts of Semen Coiciss, 10～20 parts, Fructus Hordei Germinatus, 10～15 parts of Rhizomadioscoreae, 10～20 parts of Fructus Corni, 5～10 parts of Radix Glycyrrhizae Preparatas.
Preferably, the medicament for the treatment of ocular myasthenia gravis of the present invention is to be made up of the material of following weight proportioning: 30 parts of the Radixs Astragali, 25 parts of Radix Codonopsis, 15 parts of the Rhizoma Atractylodis Macrocephalaes, 20 parts, Poria, 15 parts of Rhizoma Cimicifugaes, 12 parts of Radix Bupleuri, 12 parts of Fructus Lycii, 15 parts of Radix Angelicae Sinensis, 12 parts of Pericarpium Citri Reticulataes, 20 parts of Semen Cuscutae, 15 parts of Semen Coiciss, 15 parts, Fructus Hordei Germinatus, 10 parts of Rhizomadioscoreae, 10 parts of Fructus Corni, 5 parts of Radix Glycyrrhizae Preparatas.
More preferably, described medicament can be tablet, dispersible tablet, capsule or decoction.
Whole compositions of the medicament for the treatment of ocular myasthenia gravis of the present invention are all natural materials, and safety is better, and curative effect is clear and definite, are suitable for large-scale promotion clinically.
Detailed description of the invention
Further illustrate the present invention below by embodiment.It should be understood that embodiments of the invention are for the present invention instead of limitation of the present invention are described.The simple modifications that essence according to the present invention is carried out the present invention all belongs to the scope of protection of present invention.Except as otherwise noted, the percent otherwise in the present invention is percetage by weight.
Embodiment decoction of the present invention
Take 30 grams of the Radixs Astragali, 25 grams of Radix Codonopsis, 15 grams of the Rhizoma Atractylodis Macrocephalaes, 20 grams, Poria, 15 grams of Rhizoma Cimicifugaes, 12 grams of Radix Bupleuri, 12 grams of Fructus Lycii, 15 grams of Radix Angelicae Sinensis, 12 grams of Pericarpium Citri Reticulataes, 20 grams of Semen Cuscutae, 15 grams of Semen Coiciss, 15 grams, Fructus Hordei Germinatus, 10 grams of Rhizomadioscoreae, 10 grams of Fructus Corni, 5 grams of Radix Glycyrrhizae Preparatas, add 1000 milliliters, water, and cold water is fried boiling 20 minutes, filter, obtain decoction of the present invention.
Experimental example
Chinese medicine of the present invention is extensive in clinical practice for many years.Treat 25 routine ocular myasthenia gravis patients, make a definite diagnosis with go to the hospital neostigmine or the edrophonium chloride test positive in Jun Jing county.Wherein male 9 examples, the age is in 20-60 year, and average 35 years old, female's 16 examples, the age was 20-40 year, average 28 years old.
Use the decoction making in embodiment 1 to treat, 1 dose of every day, day takes 4 times, each 150～200ml.
Curative effect determinate standard:
Cure: the unable symptom and sign of the eye muscle such as blepharoptosis, diplopia disappears nothing morbidity in 1 year.
Effective: clinical symptoms is obviously improved, slight blepharoptosis or diplopia, slight on daily life impact;
Effective: clinical symptoms is improved, and to a certain degree affects daily life;
Invalid: clinical symptoms is unchanged or increase the weight of.
Through the treatment of a course for the treatment of (2 months), 25 routine ocular myasthenia gravis patient 23 examples are cured, and 1 routine patient is effective, and 1 routine patient is effective, and during whole treatment, does not observe obvious untoward reaction.
Claims (3)
1. a medicament for the treatment of ocular myasthenia gravis, is characterized in that, it is to be made up of the material of following weight proportioning: 20～60 parts of the Radixs Astragali, 15～60 parts of Radix Codonopsis, 10～20 parts of the Rhizoma Atractylodis Macrocephalaes, 10～30 parts, Poria, 10～20 parts of Rhizoma Cimicifugaes, 10～20 parts of Radix Bupleuri, 10～15 parts of Fructus Lycii, 10～30 parts of Radix Angelicae Sinensis, 10～15 parts of Pericarpium Citri Reticulataes, 5～10 parts of Radix Glycyrrhizae Preparatas, 10～25 parts of Semen Cuscutae, 10～30 parts of Semen Coiciss, 10～20 parts, Fructus Hordei Germinatus, 10～15 parts of Rhizomadioscoreae, 10～20 parts of Fructus Corni, 5～10 parts of Radix Glycyrrhizae Preparatas.
2. the medicament for the treatment of ocular myasthenia gravis according to claim 1, is characterized in that, it is to be made up of the material of following weight proportioning: 30 parts of the Radixs Astragali, 25 parts of Radix Codonopsis, 15 parts of the Rhizoma Atractylodis Macrocephalaes, 20 parts, Poria, 15 parts of Rhizoma Cimicifugaes, 12 parts of Radix Bupleuri, 12 parts of Fructus Lycii, 15 parts of Radix Angelicae Sinensis, 12 parts of Pericarpium Citri Reticulataes, 20 parts of Semen Cuscutae, 15 parts of Semen Coiciss, 15 parts, Fructus Hordei Germinatus, 10 parts of Rhizomadioscoreae, 10 parts of Fructus Corni, 5 parts of Radix Glycyrrhizae Preparatas.
3. the medicament for the treatment of ocular myasthenia gravis according to claim 1, is characterized in that, described medicament can be tablet, dispersible tablet, capsule or decoction.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410464437.0A CN104173853A (en) | 2014-09-12 | 2014-09-12 | Drug for treating ocular myasthenia gravis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410464437.0A CN104173853A (en) | 2014-09-12 | 2014-09-12 | Drug for treating ocular myasthenia gravis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104173853A true CN104173853A (en) | 2014-12-03 |
Family
ID=51955379
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410464437.0A Pending CN104173853A (en) | 2014-09-12 | 2014-09-12 | Drug for treating ocular myasthenia gravis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104173853A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105288561A (en) * | 2015-11-30 | 2016-02-03 | 吕翠云 | Traditional Chinese medicine composition for treating eye myasthenia gravis |
| CN105597064A (en) * | 2016-01-29 | 2016-05-25 | 宋石磊 | Traditional Chinese medicine composition for treating eye myasthenia gravis |
| CN108524748A (en) * | 2018-07-13 | 2018-09-14 | 乞国艳 | Treat the Chinese medicine composition that myasthenia gravis merges fash |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1966033A (en) * | 2006-09-26 | 2007-05-23 | 方利泉 | Medicament for treating eyelid ptosis and myasthenia gravis and method for preparing same |
-
2014
- 2014-09-12 CN CN201410464437.0A patent/CN104173853A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1966033A (en) * | 2006-09-26 | 2007-05-23 | 方利泉 | Medicament for treating eyelid ptosis and myasthenia gravis and method for preparing same |
Non-Patent Citations (2)
| Title |
|---|
| 刘建萌: "补中益气汤重用黄芪治疗重症肌无力25例临床观察", 《辽宁中医杂志》 * |
| 孙伯青: "加味补中益气汤治疗"眼肌型重症肌无力"", 《甘肃中医》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105288561A (en) * | 2015-11-30 | 2016-02-03 | 吕翠云 | Traditional Chinese medicine composition for treating eye myasthenia gravis |
| CN105597064A (en) * | 2016-01-29 | 2016-05-25 | 宋石磊 | Traditional Chinese medicine composition for treating eye myasthenia gravis |
| CN108524748A (en) * | 2018-07-13 | 2018-09-14 | 乞国艳 | Treat the Chinese medicine composition that myasthenia gravis merges fash |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104258310A (en) | Traditional Chinese medicine for curing hepatic depression syndrome type melancholia | |
| CN104147455A (en) | Preparation for treating ocular myasthenia gravis | |
| CN103463417B (en) | Traditional Chinese medicine used for treating irritable bowel syndrome | |
| CN101091769B (en) | Medicine for treating and preventing esophagus cancer and gastric cancer, and preparation method | |
| CN100372558C (en) | Medicine for treating leucocytopenia caused after tumor radiotherapy and chemotherapy | |
| CN104173853A (en) | Drug for treating ocular myasthenia gravis | |
| CN102526635B (en) | Medicament for treating premenstrual stress syndrome and preparation method thereof | |
| CN104547633B (en) | A kind of Chinese medicine composition for treating cervical spondylopathy and preparation method thereof | |
| CN104173950A (en) | Chinese herbal medicine composition for treating prostatic cancer | |
| CN107243022A (en) | Traditional Chinese medicine pill for the treatment of cancer and preparation method thereof | |
| CN102988887A (en) | Chinese medicament for treating ovarian cyst | |
| CN103405680A (en) | Traditional Chinese medicine decoction used for treatment of herpes zoster around eyes | |
| CN104147456A (en) | Decoction for treating ocular myasthenia gravis | |
| CN101007159B (en) | Traditional Chinese medicine for preventing and controlling tumor | |
| CN102872353B (en) | Medicament for treating hypertension dizzy | |
| CN105477330A (en) | Traditional Chinese medicine composition for treating arrhythmia | |
| CN104435545A (en) | Traditional Chinese medicine preparation for treating leucopenia caused by benzene poisoning | |
| CN103494939A (en) | Traditional Chinese medicine for treating senile habitual constipation | |
| CN104225016A (en) | Drug composition for treating spleen and stomach deficiency type chronic atrophic gastritis | |
| CN104042739A (en) | Traditional Chinese medicine for treating prospermia | |
| CN103893629A (en) | Chinese medicinal composition for treating child anorexia | |
| CN103550477A (en) | Medicament for treating herpes zoster | |
| CN104547406A (en) | Traditional Chinese medicine for treating heart disease | |
| CN101983712A (en) | Novel medicament for treating coronary heart disease | |
| CN105031522A (en) | Yu'naoxin medicament |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20141203 |
|
| WD01 | Invention patent application deemed withdrawn after publication |